-
Government & Regulation
![]()
Curacao and St Maarten Insurance Industry – Governance, Risk and Compliance
GlobalData’s ‘Curacao and St Maarten Insurance Industry – Governance, Risk and Compliance’ report is the result of extensive research into the insurance regulatory framework in Curacao and St Maarten. It provides detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation and transit insurance. The report specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries. The report brings together GlobalData’s research, modeling and analysis expertise, giving...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-1891 in Hypothyroidism
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-1891 in Hypothyroidism Drug Details: ST-1891 is under development for the treatment of primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Glaucoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-266 in Glaucoma Drug Details:ST-266 is under development for the treatment of ocular hypertension, radiation-induced dermatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Optic Neuritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Optic Neuritis Drug Details: ST-266 is under development for the treatment of ocular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-101 in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-101 in Hepatocellular Carcinoma Drug Details:ST-101 is under development for the treatment of hematologic malignancies including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-101 in Uveal Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-101 in Uveal Melanoma Drug Details:ST-101 is under development for the treatment of hematologic malignancies including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-101 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-101 in Metastatic Melanoma Drug Details:ST-101 is under development for the treatment of hematologic malignancies including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-316 in Synovial Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Synovial SarcomaDrug Details:ST-316 is under development for the treatment of breast cancer, hematological tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-316 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Metastatic MelanomaDrug Details:ST-316 is under development for the treatment of breast cancer, hematological tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-101 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-101 in Esophageal Cancer Drug Details:ST-101 is under development for the treatment of hematologic malignancies including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-067 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-067 in Solid Tumor Drug Details:ST-067 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Ocular Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-266 in Ocular Hypertension Drug Details:ST-266 is under development for the treatment of ocular hypertension, radiation-induced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-067 in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-067 in Merkel Cell Carcinoma Drug Details: ST-067 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-067 in Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-067 in Renal Cell Carcinoma Drug Details:ST-067 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-316 in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Metastatic Colorectal CancerDrug Details:ST-316 is under development for the treatment of breast cancer, hematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-316 in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Metastatic Ovarian CancerDrug Details:ST-316 is under development for the treatment of breast cancer, hematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-316 in Metastatic Adenocarcinoma of The Pancreas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Metastatic Adenocarcinoma of The PancreasDrug Details:ST-316 is under development for the treatment of breast...
-
Product Insights
![]()
Union Carbide Corporation St. Charles Complex, United States
Each petrochemical complex profile includes core details such as complex name, location, complex status, start year, annual petrochemical capacity (mtpa) for the period 2015-2030, key feedstock, key products produced, operator, technology, key products capacity and capacity share of the total annual capacity of the complex. We also provide contractor details such as EPC/Design & FEED contractors for the petrochemical complex. This is an on-demand report that will be delivered upon request. The report will be delivered within 1 business day...
-
Product Insights
![]()
St. Charles Refinery, United States
St. Charles refinery is located in Louisiana, United States. The refinery is owned by Valero Energy Corp. It is operated by Valero Energy Corp. The project started its operations in 1930. St. Charles Refinery profile includes core details such as name, location, refinery type, asset status, start year, owner and equity stakes, operator, design/nameplate capacities of different processing units for the period 2010-2030, nelson complexity index (NCI) and capex. We also provide refinery maintenance information for active refineries (both historic...
-
Product Insights
![]()
St Malo Field, United States
St Malo upstream field is located in Central Planning Area, United States. The upstream field is owned by Chevron USA Inc (12.50%); Eni Petroleum US LLC (1.25%); Equinor Gulf of Mexico LLC (21.50%); Exxon Mobil Corp (1.25%); MP Gulf of Mexico LLC (25%); Union Oil Company Of California (38.50%). It is operated by Union Oil Company Of California. The project started its operations in 2014. St Malo Upstream Field profile includes core details such as name, resource type, asset status,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.